Onderneming Capstone Therapeutics Corp Other OTC
Aandelen
US14068E1091
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Novel Peptides and Other Molecules
100,0
%
| 67 | 100,0 % | 62 | 100,0 % | -7,84% |
Verkoop per regio
USD in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 67 | 100,0 % | 62 | 100,0 % | -7,84% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Toporek
CEO | Chief Executive Officer | 59 | 14-07-17 |
Edward Schultz
DFI | Director of Finance/CFO | - | - |
Matthew Lipman
BRD | Director/Board Member | 45 | 14-07-17 |
Jock Holliman
BRD | Director/Board Member | 70 | 01-09-87 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jock Holliman
BRD | Director/Board Member | 70 | 01-09-87 |
Michael Toporek
CEO | Chief Executive Officer | 59 | 14-07-17 |
Matthew Lipman
BRD | Director/Board Member | 45 | 14-07-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 157 610 | 157 610 ( 100,00 %) | 0 | 100,00 % |
Bedrijfsgegevens
Capstone Therapeutics Corp.
1275 West Washington Street Suite 104
85281, Tempe
+602-286-5520
http://www.capstonethx.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,03% | 48,16 mld. | |
-0,10% | 41,73 mld. | |
+43,45% | 41,03 mld. | |
-5,26% | 28,77 mld. | |
+11,48% | 25,59 mld. | |
-22,74% | 18,96 mld. | |
+9,06% | 12,92 mld. | |
+30,01% | 12,03 mld. | |
-1,51% | 11,77 mld. |